Market Overview

Baird Remains Buyers Of Gilead Before Earnings Release

Share:
Related GILD
Wall Street's M&A Chatter From July 26: Biomarin, Sigma Designs, Colgate-Palmolive, Markel-State National
Gilead, Juniper, United, Wynn: Fast Money Picks For July 27
Biotech Fever Cools As These Players Dip On Longer-Term Views (Investor's Business Daily)
Related
Earnings Scheduled For July 28, 2017
Meet Avicanna, The First Marijuana Company To Be Accepted Into Johnson & Johnson Innovation, JLABS @ Toronto
Biotech Fever Cools As These Players Dip On Longer-Term Views (Investor's Business Daily)

In a report Thursday morning, analysts at Baird stated that they remain buyers of Gilead Sciences, Inc. (NASDAQ: GILD) before the company's fourth quarter earnings call next Tuesday, February 3.

Investors have been concerned that Gilead might disappoint after pricing concerns in the Hep C market.

"We expect Gilead's HCV franchise to return to form to close out 2014 after approval of Harvoni early on in the quarter has reversed the secondary warehousing effect of HCV patients. Our prescription trend analysis throughout the quarter indicates Sovaldi and Harvoni sales in the U.S. alone of $1.2B and $2.0B, respectively," they wrote.

The analysts also expect a major topic of discussion will be HCV pricing competition between AbbVie (NYSE: ABBV) and Express Scripts (NASDAQ: ESRX).

They stated: "We don't expect to get definitive read-through on the actual magnitude of discounts until next quarter's update but we believe Gilead's discount is likely trending towards 25%."

The consensus fourth quarter EPS estimate is expected to be $2.17, however Baird analysts estimate $2.28 EPS.

If the fourth quarter EPS comes in at $2.28, that would put Gilead at $7.90 EPS for 2014.

The firm rates Gilead at an Outperform and has a $126 price target.

Latest Ratings for GILD

DateFirmActionFromTo
Jul 2017RedburnInitiates Coverage OnBuy
Jul 2017JefferiesAssumesHold
Jun 2017Deutsche BankInitiates Coverage OnBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas FDA Analyst Ratings Trading Ideas

 

Related Articles (ESRX + ABBV)

View Comments and Join the Discussion!